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Introduction…………………………………………………………….………..…..
Neurofibromatosis type I (NF1) is a dominantly inherited disease affecting 1 in every 2,500 to 3,000 individuals, representing the most common familial cancer predisposition syndrome 1 . It is a progressive condition with variable complications occurring over the time course of the disease. The hallmark of clinical manifestation of NF1 is the development of multiple neurofibromas 2 , which are highly heterotypic benign tumors of peripheral nerve sheath mainly composed of immature Schwann cells, fibroblasts, perineurial and inflammatory matrix 3 . NF1 patients are also at high risk for the development of certain malignancies such as pheochromocytomas, childhood myeloid leukemias, neuroblastomas, rhabdomyosarcomas, and malignant peripheral nerve sheath tumors (MPNSTs) [4] [5] [6] .
Once progressing to MPNSTs, although the resection is possible, most patients will eventually relapse locally or systemically. Because of the potential involvement of underlying nerves and blood vessels, surgical removal of tumors is not always an option 7 . Furthermore, once removed, the lesions have a tendency to regrow. There is no effective treatment for NF1, nor effective approaches for predicting or preventing the occurrence of devastating complications. Thus, to discover novel biomarkers to predict and develop agents for preventing or reversing the tumorigenesis and malignant transformation of NF1 are critically needed.
Body…………………………………………………………………………………..
Although the specific cell of origin of neurofibromas and MPNSTs is uncertain, the predominant lesion associated with NF1 consists primarily of Schwann cells (60-80%) 8; 9 . Biallelic Nf1 mutations have been detected in neurofibroma and MPNSTs with NF1 10; 11 . Schwann cells in neurofibroma and MPNST have been shown to possess abnormal properties, including increased invasiveness and induction of angiogenesis 12 . Schwann cells are peripheral nerve glia originating from migrating neural crest stem cells and recent studies have shown that NF1-related malignant astrocytomas originate from neural stem cells, raising the possibility that Schwann cell precursors (progenitors) undergoing Nf1 loss of heterozygosity (LOH) during embryogenesis might be the neurofibroma-initiating cells 13 .
Moreover, several NF1 mouse models have been generated to identify the Schwann cell progenitors as the 'cells of origin' of neurofibromas and MPNSTs 14; 15 . Schwann cell progenitors differentiate by late gestation and do not persist in the adult peripheral nervous system. However, Schwann cell progenitors persist or Schwann cells dedifferentiate into progenitor-like cells in neurofibromas in NF1 16 . Much evidence indicated that the loss of the Nf1 gene in NF1 plays an important role in the initiation of tumorigenesis of neurofibromas and that all of the known NF1 phenotypes result from the inheritance or appearance of a mutant allele of the Nf1 gene 17 . The Nf1 gene product, neurofibromin, functions as a GTPase activation protein (GAP), a negative regulator of the cellular Ras kinase 18 . It has been reported that the levels of activated Ras-GTP due to the loss of neurofibromin in NF1 plexiform neurofibromas and neurogenic sarcomas were approximately 5 and 15 times higher respectively, than the levels present in non-NF1 schwannomas, supporting the hypothesis that an aberrant Ras signaling pathway is the initial event in the tumorigenesis of NF1 19; 20 . However, the molecular mechanisms of the mutational inactivation of Nf1 resulting in hyperactive Ras that leads to alterations in uncontrolled growth and dedifferentiation of Schwann cells have not been elucidated in neurofibromas and MPNSTs.
One of the most important characteristics of transformed cells is an increase in N-glycosylation of cell surface proteins, known as the 'Warren phenomenon 21 . The appropriate and accurate modification of sugar or glycan to proteins mainly depends on the action of highly specific and precisely located enzymes known as glycosyltransferases and glycosidases in different tissue and cells 22 . It has been reported that activated Ras directs N-glycosylation in transformed cells and that these changes are most readily monitored by the analysis of complex-type N-glycosylation. For example, stable transfectants of NIH3T3 cells with activated c-H-ras, c-K-ras or N-ras are tumorigenic in nude mice and display the alterations in size-distribution of cell surface glycopeptides patterns which are highly correlated with invasiveness and metastasis 23 . Transient expression of activated Ras or overexpression of wild type Ras in NIH3T3 cells resulted in the significant differences in cell surface glycoproteins shortly after transfection and was independent of morphological transformation.
It has been further reported that Ras differentially activates some glycosyltransferases to modify specific molecules involved in the malignant transformation. This is supported by the facts that the activities of the branching N-acetylglucosaminyltransferase III and V were elevated 2-to 2.5-fold whereas N-acetylglucosaminyltransferase I and II were unaltered, suggesting the formation of increased amounts of bisected glycans and structures carrying a Gal 1-GlcNAc 1-6Man-branch.
The activities of the elongating 4-galactosyltransferase and 3-N-acetylglucosaminyltransferase were increased 5-to 7-fold in transformed cells, indicating a strongly enhanced capacity to synthesize polylactosaminoglycan chains 24; 25 . Moreover, Ras-directed N-linked carbohydrate modification on cell surface components and subsequent acquisition of invasiveness apparently precedes the morphological transformation 26 . Cancer-specific oligosaccharides in the serum of patients with pancreatic cancer have been determined to be useful biomarkers for pancreatic cancer, suggesting the possibility Ras-directed glycans present on the tumor cell surface may release and circulate in peripheral blood stream of patients 27 , which may be the early diagnostic biomarkers for tumorigenesis and transformation of NF1. Because proteins travelling to the Golgi apparatus for the consequent steps of glycosylation must be bound by mannose-6-phosphate in order to attach itself to the mannose-6-phosphate receptor and 
The Expression of MGAT5B correlated with hyperactive Ras in MPNST and Ras-related malignancies.
Because MGAT5B is highly expressed in all MPNST cell lines, we focused on its role in MPNST development and metastasis.
We detect MGAT5B mRNA expression levels by qPCR and RT- Figure 11C&D ). These data suggest that RAS regulates MGAT5B mRNA expression in MPNST and Ras-related malignancies.
MAGT5B is a potential AKT phosphorylation protein.
Since MGAT5B is preferentially located in the Golgi apparatus, suggesting that posttranslational modification such as phosphorylation may promote MGAT5B transportation from the cytoplasm into Golgi apparatus. Motif Scan (www.scansite.mit.edu) graphic results indicated Ser192 (RARWTSD) in Table1. Motif scan (www.scansite.mit.edu) indicates that S192 in MGAT5B is an AKT phosphorylation site.
MGAT5B is the potential AKT phosphorylation site (Table 1) . Because AKT is highly activated in MPNSTs, we hypothesize that AKT may phosphorylates ser192 in MGAT5B to promote its trafficking plasmid to generate GST-MGAT5B fusion proteins. We purified the GST-MGAT5B fusion proteins as AKT substrates, in the present of constitutively activated AKT1 (Invitrogen, cat#2999) and
[gamma32P]ATP (Perkin Elmer), we found that GST-MGAT5B fusion protein containing S192 was phosphorylated in the presence of AKT1 whereas no phosphorylation was observed in GST-MGAT5B fusion protein with S192A mutation (Figure 13B ), suggesting S192 in MGAT5B is an AKT Figure12: wild type MGAT5B is located in the Golgi apparatus whereas mutated MGAT5Bs192A is retained in the cytoplasm. phosphorylation site.
AKT kinase blockade inhibited glycosylation of kinase receptors and arrested MGAT5B in the cytoplasm.
We treated MPNST cells with PI3K inhibitor Ly294002 in different doses for 24 hours, we found AKT kinase is inhibited ( Figure 13A ). We also detected the phosphorylation of c-MET
and EGFR was inhibited in a dose dependent manner in MPNST cells ( Figure 14A ). We hypothesized that PI3K
inhibitor-mediated phosphorylation of kinase receptors was 
MGAT5B promoted MPNST tumor lung metastasis.
We transfected pEGFPN1, pEGFPN1-MGAT5B or pEGFPN1-MGAT5BS192A plasmid respectively into STS26T cells to establish three stable cell lines. We injected these three cell lines separately into the tail veins of hairless SCID mice to observe the experimental lung tumor metastasis. After 8 weeks of breeding, mice were sacrificed, lung weights were measured and tumor micrometastasis in lung was measured under the microscope. We found 4 of 6 mice in GFP group, 5 of 6 mice in MGAT5B group showed experimental tumor lung metastasis while only I of 6 in MGAT5BS192A mice showed experimental tumor lung metastasis (Table 2 &Figure 
